Clinical application of human CD4+ CD25+ regulatory T cells for the treatment of inflammatory bowel diseases.

@article{Kanai2005ClinicalAO,
  title={Clinical application of human CD4+ CD25+ regulatory T cells for the treatment of inflammatory bowel diseases.},
  author={T. Hosokawa Kanai and Mamoru Watanabe},
  journal={Expert opinion on biological therapy},
  year={2005},
  volume={5 4},
  pages={
          451-62
        }
}
As our understanding of the immunological and genetic basis of inflammatory bowel disease (IBD) grows, potential therapeutic options are being developed at a rapid pace. Nevertheless, new drugs for IBD are needed because about half of all patients with severe ulcerative colitis (UC) eventually undergo colectomy, and a significant part of Crohn's disease (CD) patients do not respond to standard medical therapies, including immunosuppressants and TNF-alpha neutralising antibodies, or suffer from… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Similar Papers

Loading similar papers…